BioTelemetry Inc. (NASDAQ:BEAT) shares rose 1.9% during trading on Thursday . The company traded as high as $18.88 and last traded at $18.83, with a volume of 179,830 shares trading hands. The stock had previously closed at $18.47.

A number of research firms recently issued reports on BEAT. Zacks Investment Research upgraded BioTelemetry from a “hold” rating to a “buy” rating and set a $23.00 price objective on the stock in a research note on Thursday, August 4th. Benchmark Co. boosted their price objective on BioTelemetry from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, August 3rd.

The company has a market cap of $527.43 million and a P/E ratio of 40.04. The stock’s 50 day moving average price is $19.59 and its 200-day moving average price is $15.48.

BioTelemetry (NASDAQ:BEAT) last posted its earnings results on Tuesday, August 2nd. The company reported $0.20 EPS for the quarter, topping the Zacks’ consensus estimate of $0.17 by $0.03. The business earned $52.68 million during the quarter, compared to the consensus estimate of $50.27 million. The firm’s revenue for the quarter was up 17.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.12 EPS. Equities research analysts anticipate that BioTelemetry Inc. will post $0.76 earnings per share for the current year.

In other BioTelemetry news, General Counsel Peter Ferola sold 7,722 shares of BioTelemetry stock in a transaction on Thursday, September 1st. The stock was sold at an average price of $18.59, for a total value of $143,551.98. Following the completion of the sale, the general counsel now owns 35,177 shares of the company’s stock, valued at approximately $653,940.43. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Fred Broadway sold 7,525 shares of BioTelemetry stock in a transaction on Thursday, September 1st. The stock was sold at an average price of $19.25, for a total value of $144,856.25. Following the completion of the sale, the senior vice president now directly owns 61,756 shares of the company’s stock, valued at approximately $1,188,803. The disclosure for this sale can be found here.

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.